Cannabidiol may prevent the development of congestive hepatopathy secondary to right ventricular hypertrophy associated with pulmonary hypertension in rats

Anna Krzyżewska,Marta Baranowska-Kuczko,Anna Galicka,Irena Kasacka,Krzysztof Mińczuk,Hanna Kozłowska
DOI: https://doi.org/10.1007/s43440-024-00579-4
2024-03-24
Pharmacological Reports
Abstract:Pulmonary hypertension (PH) can cause right ventricular (RV) failure and subsequent cardiohepatic syndrome referred to as congestive hepatopathy (CH). Passive blood stasis in the liver can affect inflammation, fibrosis, and ultimately cirrhosis. Cannabidiol (CBD) has many beneficial properties including anti-inflammatory and reduces RV systolic pressure and RV hypertrophy in monocrotaline (MCT)-induced PH in rats. Thus, it suggests that CBD may have the potential to limit CH development secondary to RV failure. The present study aimed to determine whether chronic administration of CBD can inhibit the CH secondary to RV hypertrophy associated with MCT-induced PH.
pharmacology & pharmacy
What problem does this paper attempt to address?